Published March 16, 2016
Public health officials in the United Kingdom launched a brief investigation of incident involving about a dozen boys at a...
— William Wilberforce
The American College of Pediatricians (ACP) released a statement last month expressing concerns about Merck and Co.’s human papillomavirus vaccine, Gardasil, and its correlation to premature ovarian failure, also known as premature menopause.
The ACP’s concerns are based on two case report series published since 2013 in which girls vaccinated with Gardasil developed premature menopause. Further, there have been 213 reports of premature menopause or amenorrhea (missing menstrual periods) recorded in the Vaccine Adverse Event Reporting System (VAERS) database since Gardasil’s approval in 2006.
Most of these reports were directly and solely linked to Gardasil. The ACP noted that during the pre-HPV vaccine period, there were no cases of premature menopause recorded in VAERS. The ACP also questioned the validity of Merck’s pre-licensure Gardasil clinical trials testing the vaccine’s safety because Merck did not use a true inactive placebo but, instead, used a bioactive “placebo” that contained two of the vaccine’s ingredients, one of which was aluminum.
Read the January 2016 press release from the ACP.